Publications
5593 Results
- Journal / Conference
- European Urology Feb;85(2):171-176
- Year
- 2024
- Research Committee(s)
- Genitourinary
- PMID
- PMID37085425
- PMC
- PMC10662935
- Study Number(s)
- S1216
Bone biomarkers and subsequent survival in men with hormone sensitive prostate cancer: results from the SWOG S1216 phase III trial of androgen deprivation therapy with or without orteronel
- Journal / Conference
- Journal of Clinical Oncology Jul 1;42(19):2295-2305
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID38547438
- Study Number(s)
- CTSU/C80702
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials
- Journal / Conference
- Leukemia Jan;38(1):58-66
- Year
- 2024
- Research Committee(s)
- Leukemia
- PMID
- PMID37935977
- Study Number(s)
- S1203
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
- Journal / Conference
- Clinical Cancer Research Jan 17;30(2):444-449
- Year
- 2024
- Research Committee(s)
- Genitourinary
- PMID
- PMID37966367
- PMC
- PMC10824507
- Study Number(s)
- S1314
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
- Journal / Conference
- Clinical Cancer Research Jan 5;30(1):33-38
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID37882676
- PMC
- PMC10842092
- Study Number(s)
- S1609
A phase II basket trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia
- Journal / Conference
- ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), oral
- Year
- 2024
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1314
Predicting clinical outcomes in the S1314-COXEN Trial using a Multimodal Deep Learning Model Integrating Histopathology, Cell Types, and Gene Expression
- Journal / Conference
- ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), TIPS, poster
- Year
- 2024
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S2200
PAPMET2 A Phase II Randomized Trial of Cabozantinib with or without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma (PRCC): SWOG S2200)
- Journal / Conference
- ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), TIPS, poster
- Year
- 2024
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S2210
SWOG S2210: A PHASE II STUDY OF NEOADJUVANT CARBOPLATIN FOR LOCALIZED, HIGH RISK PROSTATE CANCER WITH GERMLINE BRCA1/2 MUTATIONS
- Journal / Conference
- ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), oral; J Clin Oncol 42, 2024 (suppl 4; abstr LBA531)
- Year
- 2024
- Research Committee(s)
- Genitourinary
- Study Number(s)
- CTSU/A031501
AMBASSADOR Alliance A031501: Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma (MIBC) vs Observation
- Journal / Conference
- ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), poster
- Year
- 2024
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1216